Join us to discover how our API expertise can empower your business
June 19th - 21st, 2024
Shanghai New International Expo Center, ChinaOur Team at CPHI China 2024
-
Deepak Sapra
CEO, Pharmaceutical Services And Active Ingredients
-
Nirav K Shah
Vice President and Head - North Asia
-
Tammy Tang
Director - Sales and Marketing
-
Kundan Reddy
Associate Director -
Sales and Marketing -
Jayce Yang
Sales Manager
About CPHI China 2024
CPHI & PMEC China is Asia's premier pharmaceutical event, bringing together suppliers and buyers across the entire pharmaceutical supply chain. Held in Shanghai at the Shanghai New International Expo Center, this in-person event unites the Chinese pharma community and fosters connections that drive innovation and industry growth.
Key highlights of CPHI China 2024:
- Unrivalled networking opportunities: Connect with thousands of pharma professionals from across the globe.
- Comprehensive exhibitor list: Discover a wide range of exhibitors across every sector of the Chinese pharmaceutical market.
- Educational events: Gain insights from industry leaders through conferences and discussions.
- Source cost-effective solutions: Find the latest advancements and solutions to optimise your business.
China 2024 is the ideal platform to expand business networks, discover new technologies, or find reliable partners.
About Dr.Reddy's API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 180+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
Our Achievements
2023
15/02/2023
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row
2023
15/02/2023
S&P Global’s Sustainability Yearbook for the 3rd year
2022
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
2020
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
2020
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
2019
05/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2019
Our Plants
Renuncia
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.